Targeting mPGES-1 as a treatment for inflammation which avoids cardiovascular risk
AssigneeThe Trustees of the University of Pennsylvania
InventorGarret FitzGerald
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for the treatment of inflammation and pain without increasing cardiovascular risk by administration of an inhibitor of mPGES-1. The invention further is related to identifying inhibitors of mPGES-1 that do not increase cardiovascular risk when administered to an individual.
Claims15
A method of treating inflammation in an individual, the method comprising administering a therapeutically effective amount of an inhibitor of microsomal prostaglandin E2 synthase (mPGES-1) to the individual, wherein the inhibitor does not increase the risk of a cardiovascular event in the individual.
A method of identifying an inhibitor of mPGES-1 that does not increase risk of a cardiovascular event in an individual, the method comprising:
- a. measuring a first level of prostacyclin and a first level of PGE2 produced by a cell that expresses mPGES-1,
- b. administering a test compound to the cell,
- c. measuring a second level of prostacylin and a second level of PGE2 produced by the cell,
- wherein a test compound that reduces the second level of PGE2 compared to the first level of PGE2 and that does not decrease the second level of prostacyclin compared to the first level of prostacyclin is identified as an inhibitor of mPGES-1 that does not increase risk of a cardiovascular event in an individual when administered to the individual.
The method of 6, wherein the cell is an endothelial cell.
The method of 9, wherein the endothelial cell is a murine endothelial cell or a human endothelial cell.
The method of 10, wherein the murine endothelial cell comprises a human mPGES-1 gene.
Dependencies are inferred from the claim text.